Phosphagenics strikes dermal option deal with US partner
This article was originally published in Scrip
Executive Summary
The Australian drug delivery technology company Phosphagenics has granted an unidentified private US dermatology firm an option to license its proprietary dermal delivery system for use with a topical drug for psoriasis.